Kite employees have spent long periods at the N. C. I. learning how to manufacture the therapy and how to treat patients in advance with chemotherapy. " We shouldnâ€™t underestimate the value and the importance of N. I. H. not only to Kite but to the whole field of engineered   therapy," Dr. Belldegrun said. When Kite signed its first deal with the cancer agency, he said, it "tapped into six years of monumental work that they had done. 